Authors: van Oosterom, AT Judson, I Verweij, J Stroobants, S di Paola, ED Dimitrijevic, S Martens, M Webb, A Sciot, R Van Glabbeke, M Silberman, S Nielsen, OS

Citation: At. Van Oosterom et al., Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study, LANCET, 358(9291), 2001, pp. 1421-1423

Authors: Therasse, P Arbuck, SG Eisenhauer, EA Wanders, J Kaplan, RS Rubinstein, L Verweij, J Van Glabbeke, M van Oosterom, AT Christian, MC Gwyther, SG

Citation: P. Therasse et al., New guidelines to evaluate the response to treatment in solid Tumors, J NAT CANC, 92(3), 2000, pp. 205-216

Authors: Piccart, MJ Green, JA Lacave, AJ Reed, N Vergote, I Benedetti-Panici, P Bonetti, A Kristeller-Tome, V Fernandez, CM Curran, D Van Glabbeke, M Lacombe, D Pinel, MC Pecorelli, S

Citation: Mj. Piccart et al., Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group, J CL ONCOL, 18(6), 2000, pp. 1193-1202

Authors: Le Cesne, A Judson, I Crowther, D Rodenhuis, S Keizer, HJ Van Hoesel, Q Blay, JY Frisch, J Van Glabbeke, M Hermans, C Van Oosterom, A Tursz, T Verweij, J

Citation: A. Le Cesne et al., Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group, J CL ONCOL, 18(14), 2000, pp. 2676-2684

Authors: Lhomme, C Fumoleau, P Fargeot, P Krakowski, Y Dieras, V Chauvergne, J Vennin, P Rebattu, P Roche, H Misset, JL Lentz, MA Van Glabbeke, M Matthieu-Boue, A Mignard, D Chevallier, B

Citation: C. Lhomme et al., Results of a European organization for research and treatment of cancer/early clinical studies group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix, J CL ONCOL, 17(10), 1999, pp. 3136-3142

Authors: Van Glabbeke, M van Oosterom, AT Oosterhuis, JW Mouridsen, H Crowther, D Somers, R Verweij, J Santoro, A Buesa, J Tursz, T

Citation: M. Van Glabbeke et al., Prognostic factors for the outcome of chemotherapy in advanced soft tissuesarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatmentof Cancer Soft Tissue and Bone Sarcoma Group Study, J CL ONCOL, 17(1), 1999, pp. 150-157